Avance Clinical Appoints Liahna Toy to Lead Global Early Phase Center of Excellence
核心洞察
Avance Clinical, a global full-service CRO headquartered in Australia, has appointed Liahna Toy (搜索) as Senior Vice President & Head of Early Phase Center of Excellence to accelerate high-quality early-phase trials for emerging biotech sponsors.
The Early Phase Center of Excellence supports biotech sponsors from first-in-human through Phase I into Phase II trials, combining regulatory strategy, scientific leadership, clinical operations, biometrics, and pharmacovigilance services.
The center operates through a globally integrated model across Australia, New Zealand, the United States, the United Kingdom, South Korea, Taiwan and India, leveraging Australia's Clinical Trial Notification scheme and R&D Tax Incentive for cost-efficient development pathways.
Avance Clinical, a global full-service contract research organization (CRO) headquartered in Australia, has announced the appointment of Liahna Toy (搜索) as Senior Vice President & Head of Early Phase Center of Excellence. The appointment reinforces the company's strategic focus on accelerating high-quality early-phase trials for emerging biotech sponsors.
Strategic Focus on Early-Phase Development
Avance Clinical's Early Phase Center of Excellence supports biotech sponsors from first-in-human (FIH) through Phase I into Phase II trials. The center combines regulatory strategy, scientific and medical leadership, clinical operations, biometrics, pharmacovigilance, and tailored project delivery to streamline early development processes.
Liahna Toy (搜索) brings extensive global experience in early-phase clinical development to her new role. She will work across Avance Clinical's scientific, operational, and partnership leaders to align strategy and execution, providing biotechs with a clear and predictable path through critical inflection points. Under her leadership, the Early Phase Center of Excellence focuses on helping biotechs move efficiently from pre-clinical readiness to FIH, generate early safety and pharmacokinetic readouts, and produce decision-grade data to support investment, partnering, or regulatory engagement.
"Early phase development sets the trajectory for a program," said Toy. "Biotechs need a CRO partner that understands both scientific complexity and capital efficiency. Our teams are focused on de-risking programs, accelerating timelines, and delivering globally accepted data that sponsors can use with confidence."
Global Integrated Model
The company's Early Phase Center of Excellence operates through a globally integrated model across Australia, New Zealand, the United States, the United Kingdom, South Korea, Taiwan and India. This approach provides consistent governance and regional execution expertise, giving sponsors greater flexibility in where they run studies while maintaining continuity in oversight, quality and delivery.
The model leverages the Australian Advantage, which includes rapid start-up under the Clinical Trial Notification (CTN) scheme, globally accepted data to support FDA and EMA pathways, and cost efficiencies through Australia's R&D Tax Incentive. These factors help sponsors start smart, preserve capital and progress with confidence as programs expand internationally.
"For global biotechs, this creates a practical and cost-efficient pathway to advance assets without compromising scientific rigor," added Toy. "Australia's multicultural population support targeted recruitment across priority therapeutic areas, while maintaining a high bar for data quality and operational execution."
Company Background
Avance Clinical is the largest premium full-service Australian headquartered CRO delivering high-quality clinical trials across multiple regions including Australia, New Zealand, Asia, North America, United Kingdom and Europe for biotechs. With more than 30 years of experience and expertise across 250+ indications, Avance Clinical supports programs from pre-clinical consulting to later-phase trials, backed by deep regulatory, clinical, and operational capability. The company has received multiple Frost & Sullivan (搜索) CRO Market Leadership and Customer Value Leadership awards.
The company will be attending BIO-Europe Spring 2026, March 23-25 in Lisbon, Portugal, where biotech leaders advancing Phase I programs are invited to schedule partnering meetings with Avance Clinical's team via the BIO-Europe Spring partnering platform.